278 related articles for article (PubMed ID: 22583454)
1. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
[TBL] [Abstract][Full Text] [Related]
2. A review of patient-reported outcome labels in the United States: 2006 to 2010.
Gnanasakthy A; Mordin M; Clark M; DeMuro C; Fehnel S; Copley-Merriman C
Value Health; 2012 May; 15(3):437-42. PubMed ID: 22583453
[TBL] [Abstract][Full Text] [Related]
3. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
4. Potential of patient-reported outcomes as nonprimary endpoints in clinical trials.
Gnanasakthy A; Lewis S; Clark M; Mordin M; DeMuro C
Health Qual Life Outcomes; 2013 May; 11():83. PubMed ID: 23675876
[TBL] [Abstract][Full Text] [Related]
5. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.
Hao Y
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):407-20. PubMed ID: 20715918
[TBL] [Abstract][Full Text] [Related]
7. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
[TBL] [Abstract][Full Text] [Related]
10. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims.
Coons SJ; Kothari S; Monz BU; Burke LB
Clin Pharmacol Ther; 2011 Nov; 90(5):743-8. PubMed ID: 21993428
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
12. Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force.
Matza LS; Patrick DL; Riley AW; Alexander JJ; Rajmil L; Pleil AM; Bullinger M
Value Health; 2013 Jun; 16(4):461-79. PubMed ID: 23796280
[TBL] [Abstract][Full Text] [Related]
13. A tale of three labels: translating the JUPITER trial data into regulatory claims.
Ridker PM
Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
[TBL] [Abstract][Full Text] [Related]
14. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB
J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228
[TBL] [Abstract][Full Text] [Related]
15. US FDA patient-reported outcome guidance: great expectations and unintended consequences.
Fehnel S; DeMuro C; McLeod L; Coon C; Gnanasakthy A
Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):441-6. PubMed ID: 23977972
[TBL] [Abstract][Full Text] [Related]
16. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.
Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M;
Value Health; 2003; 6(5):522-31. PubMed ID: 14627058
[TBL] [Abstract][Full Text] [Related]
17. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
Brozek JL; Guyatt GH; Schünemann HJ
Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
[TBL] [Abstract][Full Text] [Related]
18. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.
Basch E
Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448
[No Abstract] [Full Text] [Related]
19. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
20. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.
Wiklund I
Fundam Clin Pharmacol; 2004 Jun; 18(3):351-63. PubMed ID: 15147288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
